Lorlatinib for the Treatment of Inflammatory Myofibroblastic Tumor after Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report.

Autor:	Yagi T; Department of Outpatient Chemotherapy, Osaka International Cancer Institute, Japan., Kukita Y; Laboratory of Genomic Pathology, Osaka International Cancer Institute, Japan., Matsuoka H; Department of Orthopedic Surgery, Osaka International Cancer Institute, Japan., Wakamatsu T; Department of Orthopedic Surgery, Osaka International Cancer Institute, Japan., Tamiya H; Department of Orthopedic Surgery, Osaka International Cancer Institute, Japan., Watanabe M; Department of Orthopedic Surgery, Osaka International Cancer Institute, Japan., Kakunaga S; Department of Orthopedic Surgery, Osaka International Cancer Institute, Japan., Takenaka S; Department of Orthopedic Surgery, Osaka International Cancer Institute, Japan., Kubo C; Department of Pathology, Osaka International Cancer Institute, Japan., Hashii Y; Department of Pediatrics, Osaka International Cancer Institute, Japan., Nakanishi K; Department of Diagnostic and Interventional Radiology, Osaka International Cancer Institute, Japan.
Jazyk:	angličtina
Zdroj:	Internal medicine (Tokyo, Japan) [Intern Med] 2024 Jul 25. Date of Electronic Publication: 2024 Jul 25.
DOI:	10.2169/internalmedicine.3262-23
Abstrakt:	Inflammatory myofibroblastic tumors (IMTs) are rare sarcomas composed of myofibroblastic and fibroblastic cells, accompanied by inflammatory cell infiltration. Many IMTs exhibit clonal rearrangement of anaplastic lymphoma kinase (ALK). We herein report a 56-year-old woman with uterine IMT harboring a thrombospondin-1::ALK fusion that developed after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Laboratory data before systemic therapy indicated increased interleukin-6 and severe leukocytosis. The patient was treated with lorlatinib; however, the response duration was approximately two months. Similar case reports need to be compiled and evaluated to elucidate the efficacy of lorlatinib in post-allo-HSCT IMT with ALK rearrangement.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu